Vaxil Bio EBITDA vs. Book Value Per Share

VXL Stock  CAD 0.01  0.00  0.00%   
Considering Vaxil Bio's profitability and operating efficiency indicators, Vaxil Bio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Vaxil Bio's ability to earn profits and add value for shareholders.
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
(252.00)
Current Value
(264.60)
Quarterly Volatility
1.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Vaxil Bio's Income Quality is fairly stable compared to the past year. Net Debt To EBITDA is likely to climb to 3.88 in 2024, whereas Book Value Per Share is likely to drop 0.01 in 2024.
For Vaxil Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vaxil Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vaxil Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vaxil Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vaxil Bio over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Vaxil Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaxil Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaxil Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Vaxil Bio Book Value Per Share vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Vaxil Bio's current stock value. Our valuation model uses many indicators to compare Vaxil Bio value to that of its competitors to determine the firm's financial worth.
JavaScript chart by amCharts 3.21.15ERE-UNALA-PAAPSVXL 0510152025 0200M400M600M800M1B1.2B
Vaxil Bio is rated first in ebitda category among its peers. It is rated first in book value per share category among its peers . At this time, Vaxil Bio's EBITDA is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vaxil Bio's earnings, one of the primary drivers of an investment's value.

Vaxil Book Value Per Share vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Vaxil Bio

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(252)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Vaxil Bio

Book Value per Share

 = 

Common Equity

Average Shares

 = 
0.01 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Vaxil Book Value Per Share Comparison

Vaxil Bio is currently under evaluation in book value per share category among its peers.

Vaxil Bio Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Vaxil Bio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vaxil Bio will eventually generate negative long term returns. The profitability progress is the general direction of Vaxil Bio's change in net profit over the period of time. It can combine multiple indicators of Vaxil Bio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income4.2 M2.3 M
Operating Income(254.00)(266.70)
Income Before Tax(254.00)(266.70)
Net Loss-254 K-266.7 K
Total Other Income Expense Net4.5 K4.7 K
Income Tax Expense12.7 K13.3 K
Net Loss-254 K-266.7 K
Net Loss-1.1 M-1.2 M
Net Interest Income3.6 K3.8 K
Interest IncomeKK
Change To Netincome63 K59.9 K
Income Quality 2.21  2.32 

Vaxil Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Vaxil Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vaxil Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vaxil Bio's important profitability drivers and their relationship over time.

Use Vaxil Bio in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vaxil Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxil Bio will appreciate offsetting losses from the drop in the long position's value.

Vaxil Bio Pair Trading

Vaxil Bio Pair Trading Analysis

The ability to find closely correlated positions to Vaxil Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vaxil Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vaxil Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vaxil Bio to buy it.
The correlation of Vaxil Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vaxil Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vaxil Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vaxil Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Vaxil Bio position

In addition to having Vaxil Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cry Crypto Assets Thematic Idea Now

Cry Crypto Assets
Cry Crypto Assets Theme
An experimental p2p digital currency that is accepted by many vendors in null. The Cry Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cry Crypto Assets Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Vaxil Stock Analysis

When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.